Synta Pharmaceuticals Corp.  

(Public, NASDAQ:SNTA)   Watch this stock  
Find more results for SNTA
0.295
+0.035 (13.30%)
Jul 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.26 - 0.31
52 week 0.15 - 2.37
Open 0.27
Vol / Avg. 645,589.00/745,366.00
Mkt cap 39.41M
P/E     -
Div/yield     -
EPS -0.40
Shares 137.81M
Beta 1.05
Inst. own 15%
Jun 22, 2016
Synta Pharmaceuticals Corp at JMP Securities Life Sciences Conference
Jun 10, 2016
Synta Pharmaceuticals Corp at Jefferies Healthcare Conference
Apr 14, 2016
Synta Pharmaceuticals Conference Call to Discuss Definitive Merger Agreement to Acquire Madrigal Pharmaceuticals Inc - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -43.19% -81.33%
Return on average equity -55.24% -118.87%
Employees 10 -
CDP Score - -

Address

45 HARTWELL AVE
LEXINGTON, MA 2421
United States - Map
+1-781-2748200 (Phone)
+1-781-2748228 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synta Pharmaceuticals Corp. is focused on research, development and commercialization of oncology medicines. The Company's segment is the discovery, development and commercialization of drug products. It has a clinical-stage drug candidate in oncology (ganetespib), and a small molecule cancer drug development program (heat shock protein 90 (Hsp90) inhibitor Drug Conjugate (HDC) program). It is engaged in evaluating various candidates from its HDC program, which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver a range of anti-cancer payloads. Ganetespib is a small molecule inhibitor of Hsp90, a molecular chaperone that is required for the folding and activation of various cancer-promoting proteins. It is engaged in conducting preclinical studies for its clinical candidate from the HDC program, STA-12-8666. It holds interests in its drug candidate, elesclomol, and the calcium release-activated calcium modulator (CRACM) inhibitor program.

Officers and directors

Keith R. Gollust Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Chen Schor President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Senior Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Scott Morenstein Director
Age: 39
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Bruce Kovner Independent Director
Age: 70
Bio & Compensation  - Reuters
Donald W. Kufe M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
William S. Reardon CPA Independent Director
Age: 69
Bio & Compensation  - Reuters